News

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels.

Press Releases

Biotechnology Innovation Organization (BIO)…

WASHINGTON, DC (January 7th, 2026) – Today, the Biotechnology Innovation Organization (BIO) announced the launch of the BIO Investment Council (BIC). The newly established council aims to serve small and emerging biotech innovators by increasing…

Learn more

BIO Statement on Changes Announced to the U.S…

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on changes announced to the US childhood vaccine schedule.“American health is as unique as America itself…

Learn more

BIO Statement on December 2025 ACIP Meeting

WASHINGTON, D.C. – Phyllis Arthur, Executive Vice President and Head of Health Policy and Programs of the Biotechnology Innovation Organization (BIO) released the following statement on the December 2025 ACIP meeting.“For decades, the CDC’s Advisory…

Learn more

Letters, Testimony, & Comments

Browse All

CSBA Letter to Congressional Leaders on PBM, PPRV…

Dear Congressional Leaders:On behalf of the Council of State Bioscience Associations (CSBA)—a national coalition of independent, state and territory-based organizations representing the full breadth of America’s biotechnology ecosystem—we write to…

Learn more

BIO's Comments on Advisory Committee on…

Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee…

Learn more

Testimony of BIO President & CEO John F. Crowley…

Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000…

Learn more

Amicus Briefs

Browse All

BIO Files Amicus Brief in Case Addressing Anti…

BIO filed an amicus brief in the U.S. Court of Appeals for the District of Columbia Circuit, seeking the reversal of a lower court decision that found plaintiff Vertex Pharmaceuticals’ patient assistance program in violation of the Anti-Kickback…

Learn more

BIO Files Amicus Brief in Delaware Supreme Court…

BIO filed an amicus brief in the Supreme Court of the State of Delaware, urging the Court to exclude Plaintiffs’ expert opinion, thereby ensuring that Delaware’s standard for the admission of such evidence remains consistent with the federal …

Learn more

BIO Files Amicus Briefs Supporting the Lawfulness…

On February 10, 2025, BIO filed an amicus brief in the U.S. District Court for the District of Columbia, supporting the lawfulness of plaintiff Eli Lilly's proposed 340B rebate model. The 340B Drug Pricing Program ("340B"), through which Medicaid…

Learn more